Abstract:Background: Albuvirtide is a once-weekly injectable HIV-1 fusion inhibitor. We present interim data for a phase 3 trial assessing the safety and efficacy of albuvirtide plus lopinavir-ritonavir in HIV-1-infected adults already treated with antiretroviral drugs. Methods: We carried out a 48-week, randomized, controlled, open-label non-inferiority trial at 12 sites in China. Adults on WHO-recommended first-line treatment for > 6 months with a plasma viral load > 1000 copies per mL were enrolled and randomly assigned (1:1) to receive albuvirtide (once weekly) plus ritonavir-boosted lopinavir (ABT group) or WHO-recommended second-line treatment (NRTI group). The primary endpoint was the proportion of patients with a plasma viral load below 50 copies per mL at 48 weeks. Non-inferiority was prespecified with a margin of 12%. Findings: At the time of analysis, week 24 data were available for 83 and 92 patients, and week 48 data were available for 46 and 50 patients in the albuvirtide and NRTI groups, respectively. At 48 weeks, 80.4% patients in the ABT group and 66.0% of those in the NRTI group had HIV-1 RNA levels below 50 copies per mL (difference: 14.4%, 95% CI: -3.0 to 31.9), meeting the criteria for non-inferiority. For the per-protocol population, the superiority of albuvirtide over NRTI was demonstrated (94.9% vs. 74.4%, difference: 20.5%, 95% CI: 5.7 to 35.2, p=0.01). The frequency of grade 3-4 adverse events was similar in the two groups (14.0% vs. 11.1%); the most common adverse events were diarrhea (8.6% vs. 14.1% for the ABT and NRTI groups, respectively), upper respiratory tract infections (4.3% vs. 6.1%), and grade 3-4 increases in triglyceride concentration (6.5% vs. 4.0%). Renal function was significantly more impaired at 12 weeks in the patients of the NRTI group who received TDF than in those of the ABT group (mean change in eGFR: -11.47 vs. -1.22 mL/min/1.73m2, p=0.02). Interpretation: The TALENT study is the first phase 3 trial of an injectable long-acting HIV drug. This interim analysis suggests that once-weekly albuvirtide in combination with ritonavir-boosted lopinavir is well tolerated and non-inferior to the WHO-recommended second-line regimen in patients with first-line treatment failure.Clinical Trial Number: This study is registered with ClinicalTrials.gov, number NCT02369965 and with the Chinese Clinical Trial Registry, number ChiCTR-TRC-14004276. Funding Statement: This work was supported by the Frontier Biotechnologies Inc., Ministry of Science and Technology of China (Grant No. 2013ZX09101001, 2017ZX09201007), the Beijing Municipal of Science and Technology Major Project (D141100000314005, D141100000314002, D161100000416003), the National Natural Science Foundation of China (81772165, 81571973), and Beijing Key Laboratory for HIV/AIDS Research (BZ0089). No funding bodies had any role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Declaration of Interests: The authors of this manuscript have read the journal's policy and have the following competing interests: CY, RL, JH, and DX have received salary support from Frontier Biotechnologies Inc. All authors had full access to all study data and analyses, and approved the final report. All other authors have declared that no competing interests exist.Ethics Approval Statement: The institutional ethics committee at each site reviewed and approved the protocol and the written informed consent form which was provided according to the declaration of Helsinki. Each patient gave written informed consent before undergoing study procedures. The methods were carried out in accordance with approved guidelines and regulations.

Brief communication: efficacy and safety of the dolutegravir/lamivudine dual therapy in antiretroviral treatment-experienced Chinese people living with HIV

Efficacy and Safety of Long Acting HIV Fusion Inhibitor Albuvirtide in Antiretroviral-Experienced Adults with HIV-1: Interim 48 Week Results from the Randomized, Controlled, Phase 3 Trial, Non-Inferiority TALENT Study

Effectiveness and safety of dolutegravir plus lamivudine in treating HIV in China, including outcomes of patients coinfected with tuberculosis

DTG + 3TC dual therapy for the treatment Naïve patients with viral load exceeding 500,000 copies/mL: a retrospective study

Efficacy of dolutegravir + lamivudine q.d. with food in people with TB/HIV using a rifampicin‐based regimen: A retrospective observational case series

Tolerability and effectiveness of albuvirtide combined with dolutegravir for hospitalized people living with HIV/AIDS

Virologically suppressed switch to Dolutegravir/Lamivudine 2-Drug regimen versus switch to commonly prescribed 3-Drug regimens in the United States

A preliminary study on plasma concentration, short-term efficacy, and safety profile of dolutegravir in Chinese people with HIV

Tenofovir disoproxil fumarate vs adefovir dipivoxil in Chinese patients with chronic hepatitis B after 48 weeks: a randomized controlled trial.

A Phase-IV Non-interventional Study to Assess Virological Effectiveness, Safety, and Tolerability of DTG-based Antiretroviral Therapy in HIV-1 Infected Indian Persons Living with HIV

DOLAMA 200: Effectiveness and Safety of a Dual Therapy with Dolutegravir Plus Lamivudine in Treatment-Experienced HIV-1 Infected Real World Participants in Spain

Antiretroviral Long-Term Efficacy and Resistance of Lopinavir/Ritonavir Plus Lamivudine in HIV-1-Infected Treatment-Naïve Patients (ALTERLL): 144-Week Results of a Randomized, Open-Label, Non-Inferiority Study From Guangdong, China

Effectiveness and safety of dolutegravir two‐drug regimens in virologically suppressed people living with HIV: a systematic literature review and meta‐analysis of real‐world evidence

Impact of Dolutegravir plus Lamivudine as First-Line Antiretroviral Treatment on HIV-1 Reservoir and Inflammatory Markers in Peripheral Blood

Lipid Profile and Renal Safety of Tenofovir Disoproxil Fumarate-Based Anti-Retroviral Therapy in HIV-infected Chinese Patients.

Efficacy and tolerability of dolutegravir/lamivudine versus dolutegravir/rilpivirine in switching from a three-drug regimen based on nonnucleoside reverse transcriptase inhibitors: A retrospective cohort study

P414 ASSESSMENT OF THE CHANGE IN ESTIMATED GLOMERULAR FILTRATION RATES IN TELBIVUDINE- OR LAMIVUDINE-BASED TRERAPY IN PATIENTS WITH CHRONIC HEPATITIS B

An indirect comparison of 144-week efficacy, safety, and tolerability of dolutegravir plus lamivudine and second-generation integrase inhibitor-based, 3-drug, single-tablet regimens in therapy-naive people with HIV-1

Clinical Profile and Adverse Effects of Dolutegravir Treatment in HIV-Positive Patients: A Prospective Observational Study

HIV-1 viral decay in blood and semen in antiretroviral-naïve adults initiating dolutegravir/lamivudine versus bictegravir/emtricitabine/tenofovir alafenamide

Dolutegravir based therapy showed CD4+ T cell count recovery and viral load suppression among ART naïve people living with HIV AIDS: a pilot evaluation